Veracyte Test Helps 2 in 3 High-Risk Breast Cancer Patients Skip Chemo
Updated
Updated · Reuters · May 27
Veracyte Test Helps 2 in 3 High-Risk Breast Cancer Patients Skip Chemo
5 articles · Updated · Reuters · May 27
More than two-thirds of 4,400 early high-risk breast cancer patients guided by Veracyte’s Prosigna test safely avoided chemotherapy in a randomized trial headed to ASCO.
Five-year cancer-free survival was 93.7% in the Prosigna-guided group versus 94.9% with standard care including chemotherapy, meeting non-inferiority despite less treatment.
The test measures activity across 50 genes in tumor tissue and generates a 10-year recurrence-risk score to help oncologists decide whether chemotherapy is needed.
The finding could spare many patients chemotherapy’s lasting harms, which can include infertility, early menopause, cognitive impairment and nerve damage affecting up to 43% of survivors.
Veracyte is also presenting ASCO data showing its Decipher test can predict which metastatic hormone-sensitive prostate cancer patients benefit from adding docetaxel.
Can avoiding chemo's side effects justify a slightly lower cancer survival rate for some breast cancer patients?
When one cancer drug harms memory less, how do patients choose between cognitive health and potentially longer survival?
OPTIMA Phase III: Prosigna Genomic Test Enables Majority of High-Risk ER+/HER2- Breast Cancer Patients to Avoid Chemotherapy
Overview
The OPTIMA Phase III trial marks a major milestone in early breast cancer care by showing that the Veracyte Prosigna genomic test can safely identify many high-risk patients who do not need chemotherapy, without affecting their outcomes. This large study enrolled over 4,400 patients with high clinical-risk ER+/HER2- breast cancer and compared standard chemotherapy to a Prosigna-guided approach. The results proved that using Prosigna to guide treatment is just as effective as standard care, helping clinicians reduce overtreatment and spare patients from the harsh side effects of chemotherapy while still achieving excellent results.